NCT07514260Active, not recruitingPhase 1
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 31 Mar 2026
- Start date
- 31 Mar 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- AbbVie
- Diseases
- Obesity
- NCT number
- NCT07514260
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- From 31 Mar 2026 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
Lab values
- HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
- Participant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-1, (GLP-1) agonists, Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Who the study is looking for
- Japanese participant must be first-or second-generation Japanese of full Japanese parentage.
- First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent.
- Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.
- BMI is ≥ 23.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CenExel Act- Anaheim Clinical Trials /ID# 280879 Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.